Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol

article


Verheijen, J.H.

Rijken, D.C.

Chang, G.T.G.
Fibrinolytic activity in plasma euglobulin fractions can be increased by oral administration of stanozolol. This increase is not caused by increased synthesis or release of tissue-type plasminogen activator. A decreased level of fast acting t-PA inhibition is very probably the cause of the higher activity. These results suggest that this inhibition has a regulatory role on fibrinolysis in vivo. Chemicals/CAS: desmopressin, 16679-58-6; plasminogen activator inhibitor, 105844-41-5; plasminogen activator, 9039-53-6; stanozolol, 10418-03-8, 302-96-5; Glycoproteins; Plasminogen Activators, EC 3.4.21.-; Plasminogen Inactivators; Stanozolol, 10418-03-8
Topics



















desmopressinplasminogen activatorplasminogen activator inhibitorstanozololblood and hemopoietic systemdrug efficacyfibrinolysishumanhuman cellnormal humanAdultFibrinolysisGlycoproteinsHumanKineticsPlasminogen ActivatorsPlasminogen InactivatorsReference ValuesStanozololTime Factors
TNO Identifier
229604
Repository link
https://resolver.tno.nl/uuid:6fdc934d-27e4-4fae-8a01-45eb4ea0b673
ISSN
03406245
Source
Thrombosis and Haemostasis, 51(3), pp. 396-397.
Pages
396-397
Files
To receive the publication files, please send an e-mail request to TNO Repository.